Jana Amlerová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jana Amlerová has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Hana Hrdinová
Department of Imaging Methods, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic
2 shared publicationsJan Baxa
Department of Imaging Methods University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic
2 shared publications- Marcela Kreslová
Department of Paediatrics, University Hospital, Faculty of Medicine in Pilsen, Charles University
2 shared publications Romana Kaslová
Department of Paediatrics University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic
2 shared publications- Veronika Schwarzová
Department of Paediatrics University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic
2 shared publications - Václav Koucký
Department of Paediatrics, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic
2 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (4) , 1276-1289
Real‐world effectiveness of cenobamate in drug‐resistant and ultra‐refractory epilepsy: A multicenter study
Objective: To evaluate the real‐world effectiveness, safety, and treatment retention of cenobamate (CNB) in patients with drug‐resistant epilepsy (DRE), including ultra‐refractory epilepsy (URE), high seizure burden, and extensive prior treatment history. Methods: We conducted a retrospective, multicenter study of 500 adults with DRE (focal or combined epilepsy) who were treated with CNB at three Czech tertiary epilepsy centers. Among these patients, 83.4% met criteria for URE. Seizure outcomes, treatment retention, and adverse events were analyzed, with stratification by treatment duration and cumulative ASM exposure (number of previous and concomitant anti‐seizure medications). Primary outcomes were ≥ 50% responder rate and seizure freedom at 12 months. Results: Among 436 patients with evaluable seizure data after ≥ 3 months of CNB treatment, 55.7% achieved ≥ 50% seizure reduction and 16.5% became seizure‐free. At 12 months ( n = 331), ≥ 50% response was achieved in 61.6%, and 18.1% became seizure‐free. Among patients with focal to bilateral tonic–clonic seizures or bilateral tonic–clonic seizures, 46.1% achieved seizure freedom at 12 months. CNB efficacy persisted across high cumulative ASM burden, with seizure freedom in 22.7%, 20.2%, and 10.4% of patients with ≤ 5, 6–10, and > 10 ASMs, respectively. Multivariable analyses identified high baseline seizure burden, greater cumulative ASM exposure (> 10 ASMs), and concomitant use of sodium channel blockers as independent negative predictors of treatment response. Treatment retention at 12 months was 83.0%. Significance: CNB was effective and well‐tolerated in a highly treatment‐resistant population. Although seizure freedom rates declined with increasing cumulative ASM burden, CNB retained clinically meaningful efficacy even in highly refractory patients. Plain Language Summary: The study examined the effectiveness of cenobamate in routine clinical practice in adults with highly treatment‐resistant epilepsy. In a large multicenter cohort, many patients achieved substantial seizure reduction, including complete seizure freedom, despite extensive prior treatment. Most patients remained on cenobamate during follow‐up, consistent with good effectiveness and tolerability in routine clinical practice. These findings indicate that cenobamate can offer meaningful benefits even in very difficult‐to‐treat epilepsy and may inform treatment decisions in clinical practice.
- 18 June 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (4) , 1276-1289
Open AccessReal‐world effectiveness of cenobamate in drug‐resistant and ultra‐refractory epilepsy: A multicenter study
Objective: To evaluate the real‐world effectiveness, safety, and treatment retention of cenobamate (CNB) in patients with drug‐resistant epilepsy (DRE), including ultra‐refractory epilepsy (URE), high seizure burden, and extensive prior treatment history. Methods: We conducted a retrospective, multicenter study of 500 adults with DRE (focal or combined epilepsy) who were treated with CNB at three Czech tertiary epilepsy centers. Among these patients, 83.4% met criteria for URE. Seizure outcomes, treatment retention, and adverse events were analyzed, with stratification by treatment duration and cumulative ASM exposure (number of previous and concomitant anti‐seizure medications). Primary outcomes were ≥ 50% responder rate and seizure freedom at 12 months. Results: Among 436 patients with evaluable seizure data after ≥ 3 months of CNB treatment, 55.7% achieved ≥ 50% seizure reduction and 16.5% became seizure‐free. At 12 months ( n = 331), ≥ 50% response was achieved in 61.6%, and 18.1% became seizure‐free. Among patients with focal to bilateral tonic–clonic seizures or bilateral tonic–clonic seizures, 46.1% achieved seizure freedom at 12 months. CNB efficacy persisted across high cumulative ASM burden, with seizure freedom in 22.7%, 20.2%, and 10.4% of patients with ≤ 5, 6–10, and > 10 ASMs, respectively. Multivariable analyses identified high baseline seizure burden, greater cumulative ASM exposure (> 10 ASMs), and concomitant use of sodium channel blockers as independent negative predictors of treatment response. Treatment retention at 12 months was 83.0%. Significance: CNB was effective and well‐tolerated in a highly treatment‐resistant population. Although seizure freedom rates declined with increasing cumulative ASM burden, CNB retained clinically meaningful efficacy even in highly refractory patients. Plain Language Summary: The study examined the effectiveness of cenobamate in routine clinical practice in adults with highly treatment‐resistant epilepsy. In a large multicenter cohort, many patients achieved substantial seizure reduction, including complete seizure freedom, despite extensive prior treatment. Most patients remained on cenobamate during follow‐up, consistent with good effectiveness and tolerability in routine clinical practice. These findings indicate that cenobamate can offer meaningful benefits even in very difficult‐to‐treat epilepsy and may inform treatment decisions in clinical practice.
- 15 July 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (7) , e71208
Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abscessus Eradication in a Child With Cystic Fibrosis
- 15 July 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (7) , e71208
Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abscessus Eradication in a Child With Cystic Fibrosis
- Open Access
- 18 November 2024
- Published by Wiley
Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abs. Eradication in a Child with Cystic Fibrosis
- 18 November 2024
- Published by Wiley
Open AccessElexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abs. Eradication in a Child with Cystic Fibrosis